Eli Lilly & CO Form 4 insider transactions

Eli Lilly & Co. Director Ralph Alvarez acquired 14.55 shares of common stock on June 16, 2025, as part of a compensation deferral plan, increasing his total beneficial ownership to 54,979.164 shares.

Eli Lilly & Co's Senior Vice President of Finance and Chief Accounting Officer, Donald A. Zakrowski, sold 1,000 shares of common stock for $716.41 per share on May 27, 2025, as part of a pre-established 10b5-1 trading plan.

Director Gabrielle Sulzberger acquired 6.566 shares of Eli Lilly & Co common stock at $755.11 per share on May 19, 2025, through the Lilly Directors' Deferral Plan.

Director Juan R. Luciano acquired 19.644 shares of Eli Lilly & Co (LLY) common stock on May 19, 2025, through the Lilly Directors' Deferral Plan.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock through the company's Directors' Deferral Plan.

J. Erik Fyrwald, a director at Eli Lilly & Co, acquired 13.133 shares of common stock under the company's Directors' Deferral Plan.

Director Ralph Alvarez acquired 15.561 shares of Eli Lilly & Co common stock under the company's Directors' Deferral Plan.

Ilya Yuffa, EVP & President, LLY International, sold 1,250 shares of Eli Lilly & Co. common stock at $749.24 per share on May 14, 2025, under a pre-arranged 10b5-1 trading plan.

EVP, GC & Secretary of Eli Lilly, Anat Hakim, reports transferring shares to a spousal lifetime access trust and to her spouse on May 2, 2025.

Director Gabrielle Sulzberger acquired 6.061 shares of Eli Lilly & Co. common stock under the company's Directors' Deferral Plan.

Director Juan R. Luciano acquired 18.133 shares of Eli Lilly & Co common stock under the company's Directors' Deferral Plan.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock under the Lilly Directors' Deferral Plan.

Director J. Erik Fyrwald acquired 12.123 shares of Eli Lilly & Co common stock at $818.02 per share under the Lilly Directors' Deferral Plan.

Director Ralph Alvarez acquired 14.364 shares of Eli Lilly & Co common stock at $818.02 per share under the Lilly Directors' Deferral Plan.

Director Gabrielle Sulzberger acquired 6.012 shares of Eli Lilly & Co common stock on March 17, 2025, through the Lilly Directors' Deferral Plan.

Director Juan R. Luciano acquired 17.985 shares of Eli Lilly & Co common stock at $824.76 per share on March 17, 2025, under the company's Directors' Deferral Plan.

Mary Lynne Hedley, a director of Eli Lilly & Co, acquired 12.024 shares of common stock at $824.76 per share through the Lilly Directors' Deferral Plan.

Director J. Erik Fyrwald acquired 12.024 shares of Eli Lilly & Co common stock at $824.76 per share under the company's Directors' Deferral Plan.

Director Ralph Alvarez acquired 14.246 shares of Eli Lilly & Co common stock under the Lilly Directors' Deferral Plan.

Donald Zakrowski, SVP of Finance & CAO at Eli Lilly & Co, sold 1,000 shares of common stock at $818.24 per share on March 13, 2025, under a pre-arranged 10b5-1 trading plan.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., sold a significant portion of its holdings on March 3, 2025, reducing its position by approximately $162 million.

Eric Dozier, EVP and Chief People Officer at Eli Lilly, executed restricted stock units and disposed of shares to cover tax obligations.

EVP & Pres., Mfg. Operations Edgardo Hernandez reports acquisition and disposal of Eli Lilly & Co stock and restricted stock units on March 1, 2025.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., has sold a significant portion of its holdings in multiple transactions on February 25, 2025.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reports selling shares in multiple transactions on February 24, 2025.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co, reports the sale of a portion of its common stock holdings on February 21, 2025.

Eric Dozier, EVP and Chief People Officer at Eli Lilly & Co, reported a gift of 460 common stock shares and updates to derivative security holdings.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., executed multiple sales of common stock on February 20, 2025.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., executed multiple sales of common stock on February 19, 2025, at weighted average prices ranging from $877.373 to $880.443.

Director Gabrielle Sulzberger acquired 5.784 shares of Eli Lilly & Co common stock at $857.2 per share through the Lilly Directors' Deferral Plan.